Novel Adjunctive Therapies for NeuroAIDS

$1,721,662P01FY2009MHNIH

University Of Rochester, Rochester NY

Investigators

Linked publications & trials

Paper 39080401 Paper 38883780 Paper 38023614 Paper 37964309 Paper 37693630 Paper 36041453 Paper 35335894 Paper 35312284 Paper 34798897 Paper 34774454 Paper 34728344 Paper 34671355 Paper 34103484 Paper 33839625 Paper 32447746 Paper 32341511 Paper 32114397 Paper 31978602 Paper 31742407 Paper 31660984 Paper 31619964 Paper 31525692 Paper 31496683 Paper 31491432 Paper 31472458 Paper 30627663 Paper 30617749 Paper 30421721 Paper 30325063 Paper 30289818 Paper 30129397 Paper 30069830 Paper 29783988 Paper 29729668 Paper 29604978 Paper 29594983 Paper 29573847 Paper 29553879 Paper 29402886 Paper 29290806 Paper 29061742 Paper 29059541 Paper 28279181 Paper 28134625 Paper 28128004 Paper 27916740 Paper 27879160 Paper 27559685 Paper 27456759 Paper 27401058 Paper 27352074 Paper 27329163 Paper 26996968 Paper 26716700 Paper 26674871 Paper 26571205 Paper 26556033 Paper 26520433 Paper 26472049 Paper 26227349 Paper 26195918 Paper 26112421 Paper 26082630 Paper 26063593 Paper 26026666 Paper 25834052 Paper 25671101 Paper 25652894 Paper 25645958 Paper 25608975 Paper 25523827 Paper 25522973 Paper 25468272 Paper 25457182 Paper 25264786 Paper 25226025 Paper 25174930 Paper 25122556 Paper 24920821 Paper 24910878 Paper 24646020 Paper 24563721 Paper 24552556 Paper 24550132 Paper 24389043 Paper 24237263 Paper 24210793 Paper 24044867 Paper 24027058 Paper 24025052 Paper 23905578 Paper 23761895 Paper 23737347 Paper 23702663 Paper 23680933 Paper 23645717 Paper 23620794 Paper 23612193 Paper 23546658 Paper 23546657

Abstract

HAART has altered the face of neurologic disease in people living with HIV-1, slowing its onset, and even in some cases reversing symptoms. Unfortunately, HAART has not altered the prevalence of neurologic disease, thus we hypothesize there is a reversible metabolic component of HIV-1 associated neurologic disease with molecular targets that we can define in laboratory models, design rational adjunctive neuroprotective drugs for, either singly or in combination, then test in in vitro and in vivo models of neuroAIDS, and ultimately bring the most successful of these strategies to Phase 1 trials within the award period of this grant.

View original record on NIH RePORTER →